Objectives: The incidence of central line-associated bloodstream infections (CLABSI) attributed to central venous catheters (CVCs) inserted in the emergency department (ED) is not widely reported. The goal was to report the incidence of ED CLABSI. Secondary goals included determining the effect of a CVC bundle introduced by the hospital infection prevention department to decrease CLABSI during the surveillance period.
R ecent estimates suggest nearly two of every 1,000 general emergency department (ED) visits, and 270 of every 1,000 visits for sepsis or respiratory arrest, will result in the insertion of a central venous catheter (CVC) by an emergency physician (EP). 1, 2 Additionally, EPs are placing greater number of CVCs than a decade ago. 1, 2 The reported incidence of acute mechanical complications from CVC insertion in the ED ranges from one to five per 100 CVC insertions. 3, 4 However, less is known regarding the incidence of central line-associated bloodstream infections (CLABSIs) attributed to CVCs placed in the ED. Because of the delayed nature of diagnosing CLABSIs, the EP may not be aware that a CLABSI occurred after the patient is admitted.
Since CLABSIs are considered largely preventable, the $2 billion spent annually to treat CLABSIs has attracted the attention of policymakers. 5 The Centers for Medicare and Medicaid Services has introduced payment incentives to encourage institutions to lower CLABSI rates as close to zero as possible. 6 The Joint Commission has proposed reporting data on compliance with evidence-based prevention recommendations for CVC insertion as criteria for accreditation. 7 The leading evidence-based CLABSI prevention recommendations focus on optimizing CVC insertion practices by creating CLABSI prevention bundles that include all essential equipment, optimizing hand hygiene, ensuring strict sterile technique, avoiding the femoral vein insertion site, and using a checklist to ensure compliance with all recommended processes. [8] [9] [10] Publicly reported CLABSI rates and successful prevention strategies have focused largely on intensive care unit (ICU) patients. There are few data on CLABSI rates in EDs or successful ED CLABSI prevention strategies. The National Healthcare Safety Network (NHSN) does not track or attribute CLABSIs to EDs because EDs are not considered inpatient units.
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Only one large study from an academic medical center has compared ED and ICU CLABSI rates and found them to be similar. 12 However, the data on CVC insertions originated from billing records and predated the widespread attention now placed on CLABSI prevention efforts. Also, the CLABSI definition used in this study has been updated since publication to exclude blood cultures with common skin flora when they are collected more than 1 calendar day apart and clarify the definition of primary bloodstream infections to avoid erroneously associating secondary bloodstream infections with CVCs.
Surveillance for ED CLABSI and demonstration of the effectiveness of CLABSI prevention techniques in the ED is necessary to help inform clinical operations and guideline recommendations in the very different environment of the ED. 13 The primary purpose of this study was to determine ED CLABSI rates using prospectively identified ED CVC insertions in an ED at an academic tertiary care medical center. Since a "bundle" intervention was introduced during our period of surveillance we also sought to measure the effect of introducing the CVC insertion bundle in the ED.
METHODS

Study Design
This was a prospective observational study. The Washington University Human Research Protection Office approved the study.
Study Setting and Population
This study took place over 28 months from March 2008 to June 2010 in a large academic, urban, tertiary care hospital with over 90,000 annual ED visits. Every ED chart indicating an insertion of a CVC (including "crash lines") was selected for abstraction.
Study Protocol
During our surveillance period all units of the hospital implemented "bundled" CVC insertion kits. The commercial kits (Cardinal Health, Waukegan, IL) were created specifically for the institution with input from the institution's infection prevention department. Beginning in March 2009, each kit contained infection prevention supplies including a 2% chlorehexidine gluconate in 70% isopropyl alcohol skin antiseptic (ChloraPrep; Caridan Health, Dublin, OH), sterile gown, cap, mask, sterile ultrasound probe cover with sterile gel, a checklist to ensure compliance with aseptic techniques, and all equipment necessary to perform the CVC insertion using the Seldinger technique. The catheter itself was in a separate package so a variety of CVC types could be used with the insertion kit. To perform the procedure the operator had to collect sterile gloves, the preferred catheter, and ultrasound machine, if deemed necessary. There were no additional resources (staffing or otherwise) devoted to ensuring adherence with the specific elements of the bundle.
In conjunction with the Division of Emergency Medicine's information technology section, we created a standardized electronic CVC procedure note template for the electronic health record that allowed us to query ED visits in which physicians working in the ED documented the insertion of any CVC. 14 Research assistants were trained to retrospectively review ED and inpatient medical charts for demographic data, the procedure date and time, indication, site, and method of insertion and assign the number of days each ED CVC remained in place. Nurses detailed vascular access status daily in the medical chart including the date of removal of central lines and present method of venous access. If this information was missing we searched radiology records and physician records for details regarding CVC removal. If no record indicated CVC presence or removal we defined the last day of CVC use to be the last day nursing records indicated use of a CVC. During training, each research assistant abstracted 15 charts chosen at random; interrater agreement between the principal investigator and research assistant abstraction of catheter-days was measured and feedback was provided. All standardized abstraction forms were flagged for inconsistencies and adjudicated during periodic meetings between the research assistant and principal investigator. During chart abstractor training, the kappa statistic for catheter-days between the principal investigator and each of the two research assistants was 0.9 (95% CI = 0.69 to 1.0). Research assistants were not blinded to the purpose of the study; however, they were blinded to the study outcomes.
Blood culture and hospital discharge dates for cases of ED CVC were obtained from the hospital medical informatics database. Candidate CLABSIs included all positive blood cultures from patients with CVCs inserted in the ED, from 2 calendar days after CVC insertion until 2 calendar days after that line was removed. Single positive blood cultures with suspected skin contaminants (e.g., coagulase-negative staphylococci) were excluded. CLABSIs were identified by an experienced infection prevention specialist using the NHSN April 2013 definitions from the list of candidates. 11 The primary outcome is expressed as the number of ED CLABSI per 1,000 catheter-line days. Institutional ICU catheter-days and CLABSI rates were obtained from the hospital infection prevention department's routine surveillance practices of ICUs according to updated NHSN guidelines. Duration of ED stay with a CVC in place was calculated as the time between documentation of CVC insertion and time of patient transport from the ED to a hospital bed. Discharge diagnoses were categorized using ICD-9 CM codes and the Clinical Classification Software (CCS) developed by the Agency for Healthcare Research and Quality. 15 
Data Analysis
At the study start date the ED had no formal CLABSI surveillance or prevention program, so we estimated an ED CLABSI rate of 3.0/1,000 line days (similar to reported ICU rates prior to large-scale CLABSI prevention programs) for the sample size calculation. 16 We estimated we needed to capture 4,400 ED catheter-days to obtain a significant difference compared to the institutional target rate of 0.5 CLABSI/1,000 catheter-days with 80% power and a = 0.05. We present descriptive statistics and 95% confidence intervals (CIs) for CLABSI rates. Kappa statistics were used to characterize chart reviewer performance. The chi-square test or Fisher's exact test was used for categorical variable comparisons, as appropriate, and the Mann-Whitney U-test was used to compare nonnormally distributed variables. A p-value of <0.05 was considered significant. Since the primary objective of the paper was descriptive we did not adjust the alpha for multiple comparisons. SAS version 9.2 was used for all analyses.
RESULTS
Over the 28-month study period, 98 EPs inserted 994 CVCs in 940 patients (35 patients had more than one CVC inserted on separate ED visits). The median number of insertions per physician was seven (interquartile range [IQR] = 2 to 14; Figure 1 ). Among these, 491 (49%) were inserted in females, 756 (76%) were inserted due to shock, and 238 (24%) were inserted due to lack of peripheral access. Central lines were placed in the internal jugular vein in 539 (54%) cases, subclavian vein in 172 (17%) cases, and femoral vein in 283 (28%) cases. Ultrasound guidance was used in 687 (69%) cases. The median time between ED CVC insertion and patient transfer was 2.2 hours (IQR 1 to 4 hours) and ranged from 8 minutes to 26 hours. A total of 798 (80%) patients were admitted from the ED to an ICU while 196 (20%) were admitted to a general floor. The median time a CVC placed in the ED remained in use during the hospital stay was 3 days (IQR = 2 to 7 days), and the median length of hospital stay for patients with a CVC inserted in the ED was 8 days (IQR = 4 to 13 days). ED CLABSI rates were determined from 679 patients in whom the ED CVCs remained in place for more than 2 days. Table 1 shows the number of CLABSIs, catheter-days attributed to individual ICUs and to the ED and CLABSI rates. There were a total of 4,504 ED catheter-days and 68,033 ICU catheter-days during the 28-month time period. Total catheter-days for each of the ICUs varied and ranged from a low of 6,975 catheter-days (medical ICU) to 15,321 catheter-days (surgical ICU). The ED contributed 7.7% of total institutional ICU catheter-days. Table 2 shows characteristics of the nine ED CLABSIs. The median age of patients with ED CLABSI was 52 years and ranged from 26 to 90 years. CLABSIs occurred at all three catheter insertion sites. There were no cases of ED CLABSIs associated with mucosal barrier injury as defined by updated NHSN definitions. Among the CLABSI cases, the median time from insertion to diagnosis was 7.5 days and ranged from 2 to 21 days. In six of nine cases a CLABSI was diagnosed in 8 days or less. The median number of ED catheterdays for patients who developed CLABSIs was 10 (IQR = 9 to 12 days) while the number of ED catheterdays among patients who did not develop CLABSIs was 5 (IQR = 3 to 8 days; p = 0.005). The median length of hospital stay of patients with ED CLABSIs was 13 days (IQR = 10 to 28 days), while the median length of stay among ED CVC patients without CLABSIs was 8 days (IQR = 5 to 14 days; p = 0.006). Twenty-two percent of the ED CLABSI group (n = 2) died, while 14% of the ED CVC group without CLABSI died (n = 91, p = 0.356). Table 3 shows the characteristics of CVCs inserted in the ED and ED CLABSI rates before and after the introduction of the bundle in March 2009. EPs inserted 497 (50%) before the bundle intervention and 497 CVCs (50%) after the intervention. Before the bundle, eight CLABSIs attributable to CVCs inserted in the ED occurred compared to one after the introduction of the bundle (p = 0.038). Figure 2 shows the plot of the 3-month moving average ED CLABSI rate and the 3-month pooled moving average CLABSI rate of all institutional ICUs during the study period.
DISCUSSION
In this study the rate of CLABSI from CVCs inserted in the ED was within the range of individual institutional ICU CLABSI rates, providing evidence that CVCs inserted in the ED are not at greater risk of infection than CVCs inserted in the ICU. Using updated CLABSI definitions, the ED CLABSI rate of 2.00 per 1,000 catheter-days was similar to that reported in Lemaster's study of 1.93 per 1,000 catheter-days. 12 ED CLABSIs occurred more frequently in CVCs left in place for longer periods of time, as described previously. 12 The rate of CLABSI was lowest in the cardiothoracic ICU.
Although not systematically studied, we suspect that many CVCs assigned to this unit are placed during elective and semielective procedures in the operating room prior to the patient's ICU stay. The capacity to maximize aseptic technique in the sterile operating room environment potentially explains the low CLABSI rate in the cardiothoracic ICU. 17, 18 Only one ED CLABSI was identified in the last 14 months of the study after infection prevention efforts to package necessary CVC equipment into a bundle were introduced hospital-wide. This intervention may partly explain the lower ED CLABSI rates observed in the latter part of the surveillance period. Lower CLABSI rates have been found when operators strictly adhere to hand hygiene, maximize aseptic technique, use maximal sterile barrier precautions, perform skin antisepsis with >0.5% chlorhexidine with alcohol, avoid the femoral vein as a cannulation site, and cover the site with a sterile semipermeable dressing. [8] [9] [10] 19 It is important to note that there were no efforts to track compliance with specific elements of the CLABSI prevention bundled elements or the rate of adoption by the operators. Furthermore, the study was not powered to explore the effect of this intervention, and other temporal factors may have influenced the decline in the ED CLABSI rate. Determining the adherence to CVC bundles in the ED and the effect on CLABSIs should be a subject of further research.
A significant gap exists in how best to implement CLABSI prevention efforts in settings outside of the ICU. 20 Staffing and staff culture, patient volume, the undifferentiated nature of critical illness, and timing issues may pose a significant challenge to the implementation of conventional CLABSI prevention techniques in the ED. Since NHSN excludes EDs from formal CLABSI reporting, there are no widely reportable data. Determining ED CLABSI rates requires special collaboration with hospital infection prevention personnel to track CVCs placed in the ED and provide timely follow-up. 21 Improving feedback and knowledge of both positive and negative CVC outcomes is an important implementation strategy that emphasizes the importance of active surveillance systems to track outcomes. [22] [23] [24] [25] Active surveillance will require collaborative efforts between infection prevention specialists and ED personnel if ED CVC insertion rates continue to increase. 1, 2, 20, [26] [27] [28] The findings from the PROCESS and ARISE trials in ED patients with septic shock may influence ED CVC insertion rates. In both trials aggressive early quantitative goal-directed therapy, guided by the insertion of a CVC in the ED, achieved similar results to patients treated conservatively with fewer CVC insertions. However, in those studies, half of patients in the less aggressive arms of the protocols still underwent CVC placement. 29, 30 This far outpaced insertion rates in population-based studies, suggesting approximately 20% to 25% of septic patients undergo early CVC potentially in the ED. 2, 26 Without surveillance and feedback mechanisms, ED staff may not realize the effect of CLABSI prevention initiatives or become motivated to adopt practices that disrupt traditional workflow. 20 Determining how to integrate CLABSI prevention methods into ED workflow and which interventions work best will require further research and collaboration.
LIMITATIONS
This study was constrained by its observational design. While effort was made to capture consecutive CVCs originating in the ED, lack of documentation in the medical record may have occurred resulting in loss to follow-up. Catheters lost to follow-up may have increased or decreased the ED CLABSI rate depending on whether they resulted in an ED CLABSI or contributed CLABSI-free catheter-days. Furthermore, the study was not powered to specifically address the impact of the "bundled" intervention, but we sought to assess its effect to inform future studies. Our statistical analyses assumed independent observations, and we did not adjust for the small number of patients included more than once. Last, we did not adjust for multiple comparisons, so a p-value of <0.05 must be interpreted conservatively.
Our definition of ED CLABSI did not account for CVC care that occurred once the patient left the ED. CVCs remained assigned to the ED regardless of how long the ED CVC remained in place. The new NHSN definitions are designed to minimize the reporting of infections unrelated to insertion practices; however, it is possible some CLABSIs might occur from CVC management unrelated to CVC placement. At this institution, infection prevention specialists attribute a CLABSI occurring within 7 to 10 days after the insertion to placement practices. 31 Furthermore, the NHSN rule attributes CLABSIs to units only if the qualifying criteria are present on the same day of transfer or next calendar day. For the pur- poses of this study, we did not apply the transfer rule to the ED. This could artificially increase the rate of CLABSI attributed to the ED; however, there is no guidance as to how to classify CLABSIs possibly caused by ED CVC insertion or maintenance practices.
CONCLUSIONS
The ED central line-associated bloodstream infection rate was in the range of rates reported by individual intensive care units within our institution. Further resources dedicated to surveying ED central line-associated bloodstream infections rates are necessary to determine the effect of prevention practices in the ED.
